targets

VIVA Targets 5% of India’s Louver Market with Its Next-Gen 0.7mm Aluminium System, Debuting at ACETECH MumbaiVIVA Targets 5% of India’s Louver Market with Its Next-Gen 0.7mm Aluminium System, Debuting at ACETECH Mumbai

VIVA Targets 5% of India’s Louver Market with Its Next-Gen 0.7mm Aluminium System, Debuting at ACETECH Mumbai

MUMBAI, India, Nov. 4, 2025 /PRNewswire/ -- India's architectural design landscape is set for a bold evolution as VIVA Metal Composite Panel,…

1 week ago
Supermicro Announces U.S Federal Entity to Expand Further into the Federal Market — Extensive US-Based Manufacturing of AI Server Portfolio Targets the Federal EcosystemSupermicro Announces U.S Federal Entity to Expand Further into the Federal Market — Extensive US-Based Manufacturing of AI Server Portfolio Targets the Federal Ecosystem

Supermicro Announces U.S Federal Entity to Expand Further into the Federal Market — Extensive US-Based Manufacturing of AI Server Portfolio Targets the Federal Ecosystem

Delivers AI-optimized infrastructure, and energy-efficient computing systems, from the largest design and manufacturing facility in Silicon Valley, California Continued growth…

2 weeks ago

GENESIS MAGMA RACING TRAJECTORY PROGRAM EXCEEDS TARGETS DURING FIRST YEAR ON TRACK

The Genesis Magma Racing Trajectory Program has exceeded targets in its first year on trackStaff members in the Trajectory Program…

2 weeks ago
Avacta presents first preclinical data from dual payload pre|CISION medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular TargetsAvacta presents first preclinical data from dual payload pre|CISION medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets

Avacta presents first preclinical data from dual payload pre|CISION medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets

First-in-class dual payload peptide drug conjugate delivers two complementary therapies from a single molecule with potential to overcome resistance and…

2 weeks ago
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3K Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing HyperglycPreclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3K Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglyc

Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3K Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglyc

Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT signaling in tumor cells without affecting glucose metabolismRobust…

2 weeks ago
Questex’s IHIF Asia Delivers Record Deal-Making Activity as $280B in Capital Targets APAC Hotel MarketQuestex’s IHIF Asia Delivers Record Deal-Making Activity as $280B in Capital Targets APAC Hotel Market

Questex’s IHIF Asia Delivers Record Deal-Making Activity as $280B in Capital Targets APAC Hotel Market

Major Acquisition Deal Originated at 2024 Event Highlights Conference's Role as Premier Investment Platform HONG KONG, Oct. 9, 2025 /PRNewswire/…

3 weeks ago
Flexsys Earns EcoVadis Platinum Rating and Validates Ambitious Science-Based Targets, Reinforcing Its Commitment to a Net-Zero, Sustainable Tire IndustryFlexsys Earns EcoVadis Platinum Rating and Validates Ambitious Science-Based Targets, Reinforcing Its Commitment to a Net-Zero, Sustainable Tire Industry

Flexsys Earns EcoVadis Platinum Rating and Validates Ambitious Science-Based Targets, Reinforcing Its Commitment to a Net-Zero, Sustainable Tire Industry

Milestones affirm Flexsys' leadership in sustainability, from top 1% recognition to credible near-term and net-zero emissions reduction targets, and a commitment…

3 weeks ago
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsMerus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

-   Plenary session oral presentation: Friday, October 24 10:00 -11:40 a.m. ET -   Poster presentation on preclinical evaluation of petosemtamab…

1 month ago
Quanta Therapeutics Announces First Clinical Data Presentation for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsQuanta Therapeutics Announces First Clinical Data Presentation for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Quanta Therapeutics Announces First Clinical Data Presentation for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

RADNOR, Pa. and SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held clinical-stage biopharmaceutical company…

1 month ago
ASM hosts Investor Day, provides new 2030 targets, revises H2 2025 outlookASM hosts Investor Day, provides new 2030 targets, revises H2 2025 outlook

ASM hosts Investor Day, provides new 2030 targets, revises H2 2025 outlook

Almere, The Netherlands September 23, 2025, 7:45 a.m. CET ASM International N.V. (Euronext Amsterdam: ASM) today hosts its 2025 Investor…

2 months ago